170 related articles for article (PubMed ID: 11187122)
1. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.
Dervite I; Hober D; Morel P
N Engl J Med; 2001 Jan; 344(1):68-9. PubMed ID: 11187122
[No Abstract] [Full Text] [Related]
2. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.
Hernández JA; Diloy R; Salat D; del Río N; Martínez X; Castellví JM
Haematologica; 2003 Jun; 88(6):ECR22. PubMed ID: 12801855
[No Abstract] [Full Text] [Related]
3. Hepatitis B reactivation in a patient receiving radiolabeled rituximab.
Soong YL; Lee KM; Lui HF; Chow WC; Tao M; Li Er Loong S
Ann Hematol; 2005 Jan; 84(1):61-2. PubMed ID: 15449029
[No Abstract] [Full Text] [Related]
4. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
Niscola P; Del Principe MI; Maurillo L; Venditti A; Buccisano F; Piccioni D; Amadori S; Del Poeta G
Leukemia; 2005 Oct; 19(10):1840-1. PubMed ID: 16094417
[No Abstract] [Full Text] [Related]
5. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma.
Yang SH; Kuo SH
Ann Hematol; 2008 Apr; 87(4):325-7. PubMed ID: 17932671
[No Abstract] [Full Text] [Related]
6. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
10. Concurrence of hepatitis B surface antigen and antibody in acute and chronic hepatitis B cases.
Ng KP; Saw TL
Med J Malaysia; 1994 Jun; 49(2):117-21. PubMed ID: 8090089
[TBL] [Abstract][Full Text] [Related]
11. Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?
Huo TI; Wu JC
J Gastroenterol Hepatol; 2004 Aug; 19(8):841-3. PubMed ID: 15242483
[No Abstract] [Full Text] [Related]
12. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
[TBL] [Abstract][Full Text] [Related]
14. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
Pei SN; Chen CH; Lee CM; Wang MC; Ma MC; Hu TH; Kuo CY
Ann Hematol; 2010 Mar; 89(3):255-62. PubMed ID: 19697028
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of hepatitis B virus with rituximab.
Tsutsumi Y; Kanamori H; Mori A; Tanaka J; Asaka M; Imamura M; Masauzi N
Expert Opin Drug Saf; 2005 May; 4(3):599-608. PubMed ID: 15934864
[TBL] [Abstract][Full Text] [Related]
18. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg.
Gerlich WH
Clin Infect Dis; 2007 May; 44(9):1170-2. PubMed ID: 17407034
[No Abstract] [Full Text] [Related]
19. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus infection.
Abramowicz D; Blanpain C; Knoop C
N Engl J Med; 1998 Apr; 338(18):1311-2; author reply 1312-3. PubMed ID: 9565489
[No Abstract] [Full Text] [Related]
[Next] [New Search]